Equillium to Participate in Oppenheimer’s 2026 Innovation on the Island Event
Equillium (EQ) had its "buy" rating reaffirmed by Roth Mkm. They now have a $12.00 price target on the stock.
Equillium (EQ) is now covered by B. Riley Financial, Inc.. They set a "buy" rating and a $6.00 price target on the stock.
Equillium (EQ) was given a new $6.00 price target by Raymond James Financial, Inc.. They now have a "strong-buy" rating on the stock.
Equillium Announces Poster Presentations at IMMUNOLOGY2026™, the Annual Meeting of the American Association of Immunologists